Global Obstetrics Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Nov-2017
No. of pages: 200
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

Global Obstetrics Partnering 2010 to 2017 provides the full collection of Obstetrics disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Obstetrics partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Obstetrics partnering agreement structure

Obstetrics partnering contract documents

Top Obstetrics deals by value

Most active Obstetrics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Obstetrics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Obstetrics deals.

The report presents financial deal terms values for Obstetrics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Obstetrics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Obstetrics dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Obstetrics deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Obstetrics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Obstetrics deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Obstetrics partnering deals by specific Obstetrics target announced since 2010. The chapter is organized by specific Obstetrics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Obstetrics partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Obstetrics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Obstetrics technologies and products.

Report scope

Global Obstetrics Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Obstetrics trends and structure of deals entered into by leading companies worldwide.

Global Obstetrics Partnering 2010 to 2017 includes:

Trends in Obstetrics dealmaking in the biopharma industry since 2010

Analysis of Obstetrics deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Obstetrics deal contract documents

Comprehensive access to over 3500 Obstetrics deal records

The leading Obstetrics deals by value since 2010

Most active Obstetrics dealmakers since 2010

The report includes deals for the following indications: Analgesia in labour, Breastfeeding, Fetal abnormalities, Gestational diabetes, Hemorrhage, Hemolytic disease of the newborn, Hypertension in pregnancy, Labour induction, Nausea, Pre-eclampsia, Prenatal screening, Pregnancy, Ectopic, Hydatiform mole, Miscarriage, Termination, Preterm labour, Vomiting, plus other obstetric indications.

In Global Obstetrics Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Obstetrics Partnering 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 3500 Obstetrics deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise Obstetrics rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Key benefits

Global Obstetrics Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Obstetrics deal trends since 2010

Access Obstetrics deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Obstetrics partner companies

Comprehensive access to over 750 links to actual Obstetrics deals entered into by the world's biopharma companies

Indepth review of Obstetrics deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Obstetrics opportunities

Uncover companies actively partnering Obstetrics opportunities

Global Obstetrics Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Obstetrics dealmaking
2.1. Introduction
2.2. Obstetrics partnering over the years
2.3. Obstetrics partnering by deal type
2.4. Obstetrics partnering by industry sector
2.5. Obstetrics partnering by stage of development
2.6. Obstetrics partnering by technology type
2.7. Obstetrics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Obstetrics partnering
3.1. Introduction
3.2. Disclosed financials terms for Obstetrics partnering
3.3. Obstetrics partnering headline values
3.4. Obstetrics deal upfront payments
3.5. Obstetrics deal milestone payments
3.6. Obstetrics royalty rates

Chapter 4 - Leading Obstetrics deals and dealmakers
4.1. Introduction
4.2. Most active in Obstetrics partnering
4.3. List of most active dealmakers in Obstetrics
4.4. Top Obstetrics deals by value

Chapter 5 - Obstetrics contract document directory
5.1. Introduction
5.2. Obstetrics partnering deals where contract document available

Chapter 6 - Obstetrics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Obstetrics therapeutic target

Appendices

Appendix 1 - Directory of Obstetrics deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Obstetrics deals by deal type 2010 to 2017
Appendix 3 - Directory of Obstetrics deals by stage of development 2010 to 2017
Appendix 4 - Directory of Obstetrics deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Obstetrics partnering since 2010
Figure 2: Obstetrics partnering by deal type since 2010
Figure 3: Obstetrics partnering by industry sector since 2010
Figure 4: Obstetrics partnering by stage of development since 2010
Figure 5: Obstetrics partnering by technology type since 2010
Figure 6: Obstetrics partnering by indication since 2010
Figure 7: Obstetrics deals with a headline value
Figure 8: Obstetrics deals with upfront payment values
Figure 9: Obstetrics deals with milestone payment
Figure 10: Obstetrics deals with royalty rates
Figure 11: Active Obstetrics dealmaking activity- 2010 to 2017
Figure 12: Top Obstetrics deals by value since 2010
  • 2017-2022 China Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 20-Nov-2017        Price: US 3360 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Bacterial Vaginosis Drug market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In China market, the top players include - Bayer - Pfizer - Sanofi - Piramal - Abbott - Galderma - Mission - Alkem - Xiuzheng - Teva - Perrigo......
  • 2017-2022 Europe Top Countries Bacterial Vaginosis Drug Market Report
    Published: 20-Nov-2017        Price: US 4660 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Europe Bacterial Vaginosis Drug market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Bacterial Vaginosis Drug in Europe market, especially in Germany, UK, France, Italy, Russia, Benelux, Turkey and other countries in Europe, focuses on the top players in each country, covering......
  • 2017-2022 Global Top Countries Bacterial Vaginosis Drug Market Report
    Published: 20-Nov-2017        Price: US 4960 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the global Bacterial Vaginosis Drug market size was xx million USD, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Bacterial Vaginosis Drug in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle E......
  • 2017-2022 India Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 20-Nov-2017        Price: US 3360 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Bacterial Vaginosis Drug market size was xx million USD in China, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In India market, the top players include - Bayer - Pfizer - Sanofi - Piramal - Abbott - Galderma - Mission - Alkem - Xiuzheng - Teva - P......
  • 2017-2022 North America Bacterial Vaginosis Drug Market Report
    Published: 20-Nov-2017        Price: US 4660 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the North America Bacterial Vaginosis Drug market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Bacterial Vaginosis Drug in North America market, especially in United States, Canada and Mexico, focuses on the top players in each country, covering - Bayer - Pfizer......
  • 2017-2022 United States Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 20-Nov-2017        Price: US 3360 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Bacterial Vaginosis Drug market size was xx million USD in United States, and it will be xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. In United States market, the top players include - Bayer - Pfizer - Sanofi - Piramal - Abbott - Galderma - Mission - Alkem - Xiuzheng -......
  • 2017 Top 5 Bacterial Vaginosis Drug Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 20-Nov-2017        Price: US 4960 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." The Global Bacterial Vaginosis Drug market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) of XX% from between 2016 and 2022. This report studies the global Bacterial Vaginosis Drug market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Bact......
  • 2017-2022 Asia-Pacific Top Countries Bacterial Vaginosis Drug Market Report
    Published: 20-Nov-2017        Price: US 4660 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." In 2016, the Asia-Pacific Bacterial Vaginosis Drug market size was xx million USD and it will reach xx million USD in 2022, with a CAGR of xx% between 2016 and 2022. This report studies Bacterial Vaginosis Drug in Asia-Pacific market, especially in China, Japan, Korea, Taiwan, India, Australia, Indonesia, Thailand and Philippines, focuses on the top players in each count......
  • Global and Regional Bacterial Vaginosis Drug Market Research Report 2017
    Published: 17-Nov-2017        Price: US 3500 Onwards        Pages: 132
    Summary Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South America - Middle East & Africa By Type - Rx - OTC By Application - Hospital......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs